This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 oncoalert.m-pages.com/nhMpwe/oncoa...
🚨 THIS WEEK IN ONCOLOGY 🚨
Zanidatamab-hrii just posted an improved OS hazard ratio in HER2+ gastroesophageal adenocarcinoma — and that's just the headline.
This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 oncoalert.m-pages.com/nhMpwe/oncoa... 🚨 THIS WEEK IN ONCOLOGY 🚨 Zanidatamab-hrii just posted an improved OS hazard ratio in HER2+ gastroesophageal adenocarcinoma — and that's just the headline.
0 vue
Publié le 03/09/2026 11:52
0:10
This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 oncoalert.m-pages.com/nhMpwe/oncoa...
🚨 THIS WEEK IN ONCOLOGY 🚨
Zanidatamab-hrii just posted an improved OS hazard ratio in HER2+ gastroesophageal adenocarcinoma — and that's just the headline.
0 commentaire
?